{"name":"Oncodesign Precision Medicine","slug":"oncodesign-precision-medicine","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxNTi1LSW9zcGNlZGZXbjBZSEQ0TENOb2JKc2ROQUswV1NzekRwS1ViamlZVmZzbWdhemtoVklzWEEyaE5seXllbDVWbVB6LWlJV05QUTJwcFJndXptOHZBVWZ6akVWRi1WdmFVOG16SkVremh4YVNsY0xxZkVkMFVVWDZqdUZuUDBmTE1mMjZOdldZQWwwRUI5cXRscnNfT2RHb0o1Sk81TUJRVXNLTnBQc2tzU1FNbTZkYlpJd2M2emNsQjV5eXg0TzE5eHk0OGxGeld2VEtSZHJIUmptNm9UeEtMSTBRYlNJSG5zdkhLWmpiWnUzMWdrSkI3WnFhYzF2dWhoSU90WEl5SFU1WjlyZnpqSm1rblJ2Ujc1R1RUMXNQUGNtdFlEbzFyeGlHWWhoeFhmZ2NB?oc=5","date":"2026-03-03","type":"pipeline","source":"businesswire.com","summary":"Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease - businesswire.com","headline":"Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGlFNGVqUF9qUUFKUlV2SVBGdTgzZXItRWtHUWpvVkpQalg4Z3hFbDVSajVzV2JCRHIyTUlhdjdEdnZsTUprSGZiVERMbklQYUFYMjk5MjF6LW91WWxJdVd1ZnplOVNmTEJCUkp4SGxvT3RCT2U4MUJlWUUwdjNObmtGWTliU3otMUFWektOZlp4OGpZeDh6V0RYck9hN0kyVFhqcjFxaHVTVTk2MlBVSnFZUGZhT2FoY2NLNXJVdXV6cmtTRjlVLUFxd1FkZ09KbldjOFVfdEloQlB0NUlxaG1nZ0p6YVhfNjNPUVVFLWtZOVpCTW1kVU9Ldm1EdEIxWFhWcU9KY0tZeG1QaVdrd2ZzUGwteXBk?oc=5","date":"2025-09-25","type":"pipeline","source":"businesswire.com","summary":"OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson’s Research - businesswire.com","headline":"OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNSElrbEVvTENES3Z5amZvd3htOVgxXzBsaEJvdDVJTE10NUowWnR6Z1FGdnh0Tm9tdXBWMjU0anZQMi1FSm5rdUg3MlF0RDdSNFRFMkp6MjJXVFBWeldPTXFJZFhBRzAtaW81V1ctbFcwdDRWdU11a29NR2pOR25udFh4OTFJU3J2NzRtaDRhWGdLOS0zdEh5SEpXVDJLVjFhNGp6UkhCNFhJaW50?oc=5","date":"2025-09-16","type":"pipeline","source":"BioSpace","summary":"Humanized Mouse Model Market Set to Surge USD 250.94 Million by 2034 - BioSpace","headline":"Humanized Mouse Model Market Set to Surge USD 250.94 Million by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQdVpoVzFLN09xS1hFOEkzdVc5LUZiT1NIaGVpTlhqMl9QV3pacnA5VTVjWmwwR0hmakFrSFlYMFVwajdnbmpDak44REhZY19YZ1ktX21wcWtTQ1dmTVdmOFUzU20tczZDeXZYamxZYmVTMVFFbnRqTkNkcjFZY2NrT0RtUExqZWEtNVA3eVlWVjR4Mmxib25J?oc=5","date":"2025-04-04","type":"pipeline","source":"Fierce Biotech","summary":"Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages - Fierce Biotech","headline":"Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-03-24","type":"trial","source":"businesswire.com","summary":"Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-P","headline":"Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combi","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPWGNkeE43LWFVX0d3WTdheHl6RGkxRXU3SllKSzlEREdNMV93YW1xUHRNRWp1aTZaZVhpM0RUY1JsbUljY1llX3dMalpaN0ZUZDh1Y0ZoRDg4Nk1RTTE3QzdNZGpaVzlWTndnYUFnaUtoaVBFYXBIaHZ2RXNPLU1FWHdTQzIyY3gzWjFYWW5EY1ozYzlXeURnc3QtOGxDQkFxMWlSd096TXI5a3NoVjhyRHBUdFREcTNJazhvUFdjOGtkUDJHT3ZLd1BsOEZPMy1odXNWVWh2WFM?oc=5","date":"2025-03-04","type":"pipeline","source":"businesswire.com","summary":"Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors - businesswire.com","headline":"Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPckI2Zk82R2pqeExYLXFYV2hNR2s4U2MwYzRoXzZnelNNUHltY25McjJUY2ZTR3FNY1BTMHdBdnVydkZDU1U5ejUzeW9XVTM0UXA1eTJheWhKcUthc0FPUEZpN1lBallHN1d0UzBzbEdfN194QTRfeHV2azh0REtyT1RhWkZlcTJSUW84UVYxNXVxZUlJMGJaTmU3dk1pdklmdkxCd1JVanI5ekdVVkhKWF95aE5LUTdUOHduME1YV0txbUwyYnRDX3cyTm1MTEk?oc=5","date":"2024-08-12","type":"pipeline","source":"Healio","summary":"Skyrizi outperforms Stelara in endoscopic remission at week 48 in Crohn’s disease - Healio","headline":"Skyrizi outperforms Stelara in endoscopic remission at week 48 in Crohn’s disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQMm0zTzh4dlV3SmJPZDdlRXVsVWZzY014czhFeUlORXdWOE9hSUtFZ1VGNExiaC16bTUyUTdmekZ2dDRkWHlNNGQ4VnB1MmhGdHNUSzY4Q0pHQlZZOHlEWmdZUEZKbnpMNHM0TVhaaUMwYTZNMmZFQno0SV9OT0ZVUHVDbk9hS3Bqdmc?oc=5","date":"2024-01-08","type":"pipeline","source":"pharmaphorum","summary":"Servier will apply ‘digital twin’ tech to Parkinson’s drug - pharmaphorum","headline":"Servier will apply ‘digital twin’ tech to Parkinson’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxNSlRQcVg1TGFXRFM4ejhubW5rZGlRYmozU01Zazd2VWlNNllqT2NhaWFUVzZKRWRrZm4zSXBCeHFsZUpNb29GSVFBUlNCQmQ1cWJjVFdEYVBnNk9fTlpXZDNxdUNjek9aQkZLWkE2WUdENjYzcHhQT283eW5pS0ptb2pmeEl0Vy1LVUNLcXVQWGZZd0F4SXAxQzU0eTNBOGlLNVFGLVpVemR4OXN1dWUzRW9SRHpkRG1LMU54d0hMZ1diWnFWVC1kRGd6MGcza2RBUC1oNjNkUk1kN2NyVmpjeFdnU0Y2aFUtWG1CZEU0b0RFbkg0NTJHZE9tNjBCU3pqbnJEaVBkRkZsWExQR3JmMUFON2lHX3M5VW5yTF9rMVVha2lJaXk0b2U5Tk53Vk9RVWxseGJBMWJEeHRCeGhMYWJOYndkOVlON3FKVFpTUlVzN1NMcDRIYnlYVmpZcmEySXJVXw?oc=5","date":"2022-10-19","type":"regulatory","source":"businesswire.com","summary":"EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV, Advised By ELYAN PARTNERS, Acquires a Majority Stake in ONCODESIGN SERVICES and Will File a Simplified Tender Offer on the Company's Remaining Shares - busin","headline":"EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV, Advised By ELYAN PARTNERS, Acquires a Majority Stake in ONCODESIGN SERVICES a","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-07-01","type":"deal","source":"businesswire.com","summary":"ONCODESIGN Announces the Separation of Its Two Business Lines – Service and Biotech – and Its Entry Into Exclusive Negotiations With Elyan Partners for the Sale of a Majority Stake in ONCODESIGN (Serv","headline":"ONCODESIGN Announces the Separation of Its Two Business Lines – Service and Biotech – and Its Entry Into Exclusive Negot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQRmdGR2tmeF8wMDRSZXRhTlBKc0lkRkVFNlI0Y3VvMnNBRTI4VHBza1duelpRWVBwUlVmYkhoTGdGUG9OOF9fZUF6b29NWnlaRGVyNWtpOFI5TmdIU3NJODF6MERUSlpPYWxlNXpUX0o4ZG5BcC0xRGV4TUN1d3RDeGhOSUZYYnVjQ1YzaXpSc0tWOUVpUkpiRHdGUmo4S0ZWNHdKQ3A2bVBqNXhQSl91by1MUzNxOGxDbWtIMHpaUHlXLWJYR0taNWpDcXRaTEZEME92RVVQM1FCdXQ2bkRZZEUyU0lmTy1UUEhweHJ2VQ?oc=5","date":"2021-06-28","type":"regulatory","source":"businesswire.com","summary":"Oncodesign Launches its New DRIVE-MRT™ Service Offer in Partnership with Covalab, CheMatech and ABX-CRO - businesswire.com","headline":"Oncodesign Launches its New DRIVE-MRT™ Service Offer in Partnership with Covalab, CheMatech and ABX-CRO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOdkhOUEx4eHdYVFhfSUFtZmZySFNia21rRHNaZEMtN0FfU2FXTFltR3YxQ0RlbVJaWVZJSVNsbG1tdV9LWFdyUy1hbHhjQlE2QW5ERElOdUF1YlNST3QxM3QxN04wNVFpQmNvdENPOVZieTVxSUFneUJCd0xVdkx2Zk1aT3cxTDl5ZjV1R0RjbjZOblNaVXEwd2J3WWNLbUd4VVMxWg?oc=5","date":"2017-11-03","type":"pipeline","source":"MarketsandMarkets","summary":"Patient-Derived Xenografts (PDX) Models Market Report 2025-2030, By Type, Service, and Geo - MarketsandMarkets","headline":"Patient-Derived Xenografts (PDX) Models Market Report 2025-2030, By Type, Service, and Geo","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}